| • Community pharmacy (3)
• Pfizer proposals
• COPD
• Statins
• Complementary medicine
• NHS
• Physician-assisted suicide (3)
• Prescribing
• Northern Ireland
• Medicines recycling
• Retention fees
• Reciprocity
Letters to the Editor
|
Statins
There is evidence that switching statins has consequences
From Mr J. L. Woodward, MRPharmS
In a previous letter (PJ, 23/30 December 2006, p767), I stated that
Brian Curwain was only interested in saving millions of pounds for the
taxpayer, patients’ quality of life being secondary. This referred
to him not only advocating the changeover of patients from atorvastatin
to simvastatin, but also asking community pharmacists to support him
in his quest. I also posed the question as to whether or not there was
sufficient evidence to show that the lifespan of patients undertaking
such a change in medication would not be decreased or affected in any
way.
May I refer him to the correspondence in The Lancet of 6 January, where
Rob Butler and James Wainwright, from the department of cardiology, University
Hospital of North Staffordshire, Keele University, categorically state
that such a procedure is purely for fiscal reasons and increases the
morbidity and mortality of patients with cardiovascular disease. Despite
clinical objections, the local primary care trust and the national health
care trusts imposed this changeover on the physicians.
Intervention of this nature is completely unjustified with it being against
the wishes and recommendations of the consultant cardiologists. Has the
North Staffordshire PCT advised other PCTs of this important finding — cardiac
readmissions nearly doubled and deaths increased by more than three-fold?
Personally, I do not find the reply from Dr Curwain greatly convincing
and pose the question as to whether or not such decisions should lie
in the hands of the PCTs. That role surely should be left in the hands
of health care professionals.
John L. Woodward
Stafford
|